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The cycle length dependence of the action potential duration and
the effective refractory period of the right ventricular endocar-
dium were investigated in 24 patients undergoing electrophysio-
logic studies for suspected ventricular tachycardia. The action
potential duration at 90% repolarization and the effective refrac-
tory period at twice diastolic threshold strength were measured at
the same catheter site at steady state cycle lengths of 350 to
600 ms. Both measurements decreased linearly with decreasing
cycle length, maintaining a parallel relation. When the relation
between action potential duration and effective refractory period
was expressed as the effective refractory period-action potential
duration difference, nearly constant values (range -12 to -15 ms)
were obtained at all cycle lengths.
To determine whether sodium channel blocking drugs influ-
ence the effective refractory period-action potential duration
relation in humans, measurements of these two variables were
obtained in 15 patients before and during the infusion of procain-
amide. Procainamide prolonged the action potential duration at
In vitro studies (1,2) have demonstrated that both the action
potential duration and the effective refractory period de-
crease when the cycle length is shortened. Clinical electro-
physiologic studies (3) have confirmed the cycle length
dependence of the effective refractory period in human
myocardium and studies (4,5) using monophasic action po-
tential catheters have confirmed a similar rate response of
the human action potential duration. Although these data
suggest a close relation between repolarization and excitabil-
ity in the human heart in vivo, one previous clinical study (6)
reported only poor correlation between right ventricular
action potential duration and effective refractory period
measurements. However, in that clinical study, action po-
tential duration and effective refractory period were mea-
sured at disparate right ventricular endocardial sites and lack
of a close correlation between the two variables may have
been due to site-specific variability of either action potential
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each cycle length by a near constant amount over baseline values
(p < 0.001). Procainamide also increased the effective refractory
period at each cycle length but with a greater incremental increase
at the shorter cycle lengths. The rate-dependent increase in the
effective refractory period-action potential duration difference
became significant at cycle lengths :5400 ms; at these high rates,
the effective refractory period-action potential duration difference
became positive (1.6 ms, p < 0.01 compared with baseline).
Thus, in the human ventricle, the action potential duration and
the effective refractory period have a close relation that remains
fixed over a wide range of cycle lengths. The cycle length-
dependent increase in the effective refractory period relative to
action potential duration induced by procainamide is consistent
with use dependency of sodium channel blocking drugs observed
in vitro and may be a useful marker for measuring antiarrhythmic
drug activity in vivo.
(J Am Coll CardioI1992;19:614-8)
duration or effective refractory period (7,8). A direct in vivo
comparison of human action potential duration and effective
refractory period, both measured at the same endocardial
site, has not yet been reported.
The purpose of the present clinical study was twofold.
First, having developed a technique to measure both the
action potential duration and the effective refractory period
at the same endocardial site in the human heart (9), we
wished to determine the relation of the action potential
duration and the effective refractory period in human ven-
tricular myocardium and the cycle length dependence ofthis
relation. Second, we wanted to determine the effect of a
sodium channel blocking agent, procainamide, on this rela-
tion and specifically on the cycle length dependence of this
effect. Our interest in the cycle length-dependent effects of
procainamide on the action potential duration-effective re-
fractory period relation was fostered by previous reports
(10-12) that sodium channel blocking agents alter myocar-
dial excitability properties in a rate- (or use-) dependent
fashion.
Methods
Study patients (Table 1). The study was performed in 24
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Table l. Clinical Characteristics of 24 Patients
PI Age (yr)1 Heart Ejection Plasma Procainamide
No. Gender Disease Fraction (%) Level (Jotgiml)
1 52/M CM <35 11
2 651M CAD >35 6.5
3 58/M CAD <35 10
4 58/M CAD <35 8.9
5 5liM CAD >35 6.1
6 67/M CAD >35 5.1
7 43/M CM <35 5.9
8 751M CAD >35 5.7
9 49/M CM <35 8.3
10 65/F CAD >35 5.8
11 491M CM <35 5.7
12 77/M HTN >35 NA
13 681M CAD >35 NA
14 291M CM <35 5
15 121M CAD >35 6.6
16 381M CM <35
17 58/F CAD >35
18 591M CAD NA
19 70/M NL >35
20 661M CAD >35
21 53/M CAD <35
22 681M CM <35
23 59/M CAD NA
24 74/M CAD NA
CAD == coronary artery disease with remote myocardial infarction; CM ==
cardiomyopathy; F == female; HTN == left ventricular dysfunction due to
long-standing hypertension; M == male; NA == not available: NL == no
apparent heart disease; PI == patient.
patients (22 men and 2 women) aged 38 to 77 years (mean
60 ± 3) undergoing electrophysiologic study for suspected
ventricular tachyarrhythmias. Informed consent for the
study protocol was obtained in compliance with the Stanford
University Human Subjects Committee guidelines. The un-
derlying heart disease was coronary artery disease with prior
myocardial infarction (15 patients), idiopathic dilated cardio-
myopathy (7 patients) and left ventricular dysfunction due to
longstanding hypertension (1 patient). One patient had no
apparent heart disease. Left ventricular ejection fraction was
>35% in 11 patients and <35% in 10 patients (three ejection
fraction measurements were unavailable).
Electrophysiologic study. Baseline electrophysiologic
study was performed after all antiarrhythmic drugs had been
discontinued for ~5 half-lives and patients had given written
informed consent. Standard endocardial electrodes were
positioned in the right atrium, the His position and right
ventricular apex in the usual manner. A monophasic action
potential contact electrode catheter (9,13) was positioned in
the right ventricular outflow tract. Pacing was performed at
twice diastolic threshold and 2-ms pulse width at various
cycle lengths between 350 and 600 ms in 50-ms increments.
At each cycle length, continuous pacing was performed for
~1min to assure steady state. All intracardiac electrograms
and surface electrocardiograms were recorded on a multi-
channel recorder at paper speeds of 100 to 250 mm/s.
Action potential duration and effective refractory period
determinations. Simultaneous determinations and analysis
of action potential duration and effective refractory period
have been described previously (9,14). Briefly, determina-
tion of these variables was performed during continuous
pacing from the right ventricular apex or outflow tract by a
catheter that allowed pacing and monophasic action poten-
tial recordings from nearly identical sites (9). Extrastimuli
were delivered after every 12th regular stimulus. By apply-
ing the extrastimulus through the monophasic action poten-
tial catheter, we eliminated the influence of conduction delay
between the pacing site and a separate monophasic action
potential recording site. Extrastimuli were delivered at cou-
pling intervals of 5-ms decrements until refractoriness oc-
curred. The interval between the upstroke of the depolariza-
tion of the monophasic action potential signal to the
deflection from the longest extrastimulus that failed to cap-
ture was recorded as the effective refractory period for that
paced cycle length (9). Action potential duration was mea-
sured as the interval between the monophasic action poten-
tial upstroke and the downstroke of repolarization at the 90%
repolarization level (14). By measuring both action potential
duration and effective refractory period at the same elec-
trode site, the influence of intersite variability pre~iously
reported for both intervals (3,8) was avoided.
Effect of procainamide on effective refractory period and
action potential duration. To assess the effect of procaina-
mide on these two variables, measurements were obtained at
baseline study and immediately after the completion of
intravenous administration of the drug in 15 patients. Intra-
venous procainamide was given at a standard dose of
10 mg/kg body weight infused over 20 min, followed by a
3 mg/min continuous infusion. Plasma concentration of the
drug obtained on termination of the study ranged from 5 to
11 p,g/ml (mean 5.5 ± 3.3). Procainamide levels in two
patients were unavailable.
Data evaluation and statistical analysis. Action potential
duration was measured at the level of90% repolarization and
averaged from three consecutive ventricular paced com-
plexes preceding the extrastimulus. The effective refractory
period was defined as the average of at least two determina-
tions. Data are presented as mean values ± SEM. Linear
regression analysis using a 95% confidence interval was
applied to cycle length versus action potential duration and
effective refractory period in the drug-free state.
The Hotelling T-squared test (15), a multiple variate
analysis, was used to compare the effects of procainamide on
action potential duration and effective refractory period as
compared with baseline at each cycle length. A repeated
measures analysis of variance with the Greenhouse-Geisser
correction (16) for intrasubject correlations was used to
compare the difference between effective refractory period-
action potential duration difference obtained with procaina-
mide versus that obtained at baseline as a function of cycle
length. The cycle length of 600 mswas omitted from the
statistical analysis of this comparison because data from
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Figure 1. Relation between action potential duration (APD) and
effective refractory period (ERP) with varying cycle length. Note
the parallel linear shortening of the action potential duration and the
effective refractory period with shorter cycle lengths.
Figure 2. Effect of procainamide on action potential duration (APD)
with varying cycle lengths.
3OO~-------------.....,
Figure 3. Effect of procainamide on the effective refractory period
(ERP) with varying cycle lengths.
the lines utilizing a 95% confidence interval yielded a linear
regression equation of y = 0.22x + 135 with a correlation
coefficient of 0.995 for the action potential duration and y =
0.20x + 127 with a correlation coefficient of 0.972 for the
effective refractory period. The action potential duration
was always greater than the effective refractory period at
each cycle length, with a mean difference of 18.8 ± 1.4 ms.
Effect of procainamide. Figures 2 to 4 demonstrate the
effects of procainamide on action potential duration, effec-
tive refractory period and effective refractory period-action
potential duration difference over several cycle lengths.
Procainamide significantly prolonged action potential dura-
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three patients from the procainamide group and six patients
from the baseline group were not obtained because the cycle
length in these patients was <600 ms.
Results
Stability and quality of monophasic action potential record-
ings. Once a firm contact between the tip of the monophasic
action potential catheter and the endocardial surface of the
right ventricular outflow tract was established, the quality of
the monophasic action potential recording remained satis-
factory throughout the study (which usually took 30 to
40 min to complete). The amplitude of the monophasic
action potential recording did decrease by approximately
10% to 30%; however, its shape and duration were stable at
each paced cycle length. The diastolic pacing threshold of
the electrodes remained stable and was always <OJ rnA at
current pulse width of 2ms. After ~1min ofpacing to assure
steady state at each particular cycle length, the action
potential duration was constant (variability <5% among
three consecutive measurements).
Baseline action potential duration and effective refractory
period. Figure 1 demonstrates the relation between cycle
length and action potential duration and effective refractory
period, respectively, in the 24 patients in the drug-free state.
The data at a 350-ms cycle length represent only nine
patients as a result of intolerance to such rapid pacing in the
others. The data at a 600-ms cycle length represent only 17
patients because the other 7 patients had a sinus cycle length
<600 ms.
Both the action potential duration and the effective re-
fractory period shortened linearly with a shorter cycle
length, maintaining a parallel relation. Linear regression of
Figure 4. Effect of procainamide on the effective refractory period-
action potential duration difference (ERP-APD) with varying cycle
lengths. *p < 0.01.
Discussion
This study characterizes the cycle length relation of the
action potential duration and the effective refractory period
in the human right ventricle measured simultaneously and at
the same endocardial site. In the drug-free state, both action
potential duration and effective refractory period shortened
linearly as heart rate increased, maintaining a parallel rela-
tion. These observations are in agreement with previous in
vitro and in vivo animal studies (17-19) that also showed a
close correspondence between rate-dependent changes in
action potential duration and effective refractory period. An
earlier clinical study (3) investigating the relation of the
effective refractory period and the QT interval, which is
thought to reflect the sum of the action potential durations of
all ventricular muscle cells, reported that these two measure-
tion at each cycle length by a near constant amount com-
pared with baseline values (mean 19.9 ± 1.2 ms) (Fig. 2). The
effective refractory period was increased by procainamide
by an amount similar to that of action potential duration at
cycle lengths of 600 to 450 ms, but more than action potential
duration at cycle lengths 400 and 350 ms (mean 30 + 5 at
cycle length of 600 ms; mean 37.6 + 6.1 at a cycle length of
400 ms) (Fig. 3). The greater increase in the effective
refractory period relative to the action potential duration at
shorter cycle lengths is reflected by a reduction in the
effective refractory period-action potential duration differ-
ence (Fig. 4). The effective refractory period-action potential
duration difference produced by procainamide at cycle
lengths of 600 to 450 ms is approximately -13 ms, which is
the same as the baseline difference. However, at a cycle
length :,:;400 ms, the effective refractory period-action poten-
tial duration difference becomes positive (p < 0.01).
ments decreased as the cycle length decreased. A more
recent human study (5) demonstrated a progressive decrease
in action potential duration, with an increase in ventricular
pacing rate. However, this study did not directly compare
the effects of varying cycle length on action potential dura-
tion and effective refractory period.
Importance of single-site measurement of action potential
duration and effective refractory period. Olsson et a1. (6)
measured both of these variables in the human right ventricle
and found a poor correlation. However, they measured the
two variables at different sites and at different times. Sub-
stantial variation of action potential duration and effective
refractory period occurs in measurements taken at different
sites in the ventricle (7,8). This observation emphasizes the
need to analyze the relation of action potential duration and
effective refractory period at the same ventricular site. In the
present study, measurements of both variables were ob-
tained at the same time and at the same ventricular site, thus
eliminating errors caused by spatial nonuniformity of elec-
trophysiologic properties.
The data in the present study were obtained from patients
undergoing electrophysiologic evaluation for suspected ven-
tricular tachycardia and most of these patients had docu-
mented heart disease. However, in the majority of these
patients there was little reason to assume significant disease
involvement of the right ventricle, from which recordings
were obtained. Also, linear regression analysis of the cycle
length dependence of action potential duration yielded val-
ues nearly identical to those obtained in an earlier action
potential duration investigation (4) in patients without overt
myocardial disease and the parallel changes in effective
refractory period are consistent with normal myocardium.
Possible mechanisms for drug-induced changes in the cycle
length dependence of action potential duration and effective
refractory period. The progressive shortening of the action
potential duration with increasing heart rates has been
explained by alterations in intracellular and extracellular ion
concentrations. As the heart rate increases, there is an
accumulation of extracellular potassium ions and intracellu-
lar calcium ions that hastens repolarization (20,21). Further-
more, fast heart rates shorten diastole and impede the
complete recovery of inward currents that compose the
action potential duration (4,21).
In the present study, procainamide significantly increased
the effective refractory period at each cycle length, with
greater relative increases at the shorter cycle lengths. This
finding is consistent with observations in isolated cardiac
tissue (10-12) and in in vivo canine hearts (19,22,23), which
demonstrated a rate-dependent increase in refractoriness
relative to repolarization by class I antiarrhythmic drugs.
Because an increase in refractoriness relative to repolariza-
tion reflects voltage-independent but time-dependent sup-
pression of excitability, the cycle length dependence of the
increase in the effective refractory period-action potential
duration difference may be an index for the drug's rate-
dependence of sodium channel blockade (19,22,23). In these
650
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experimental studies, the effective refractory period-action
potential duration difference after the administration of class
Ia antiarrhythmic drugs did not begin to increase compared
with baseline until the preparation was paced at a cycle
length of :5400 ms and did not become significant until the
cycle length was ;:::300 ms. This may explain why there was
only a small incremental increase in the effective refractory
period-action potential duration difference after procaina-
mide at cycle length 400 ms and why a recent study (5) did
not find any cycle length dependence of the effect of quini-
dine on human ventricular effective refractory period. Pac-
ing at a cycle length 400 ms may be at the threshold for
demonstrating rate-dependent effects of class IA antiar-
rhythmic drugs on human effective refractory period in vivo.
Other antiarrhythmic drugs with slower rate-dependence
characteristics (such as class Ie drugs or drug combinations)
may be better candidates for demonstrating significant effec-
tive refractory period increases relative to action potential
duration at clinically tolerated pacing rates.
Conclusions. The present study demonstrates a striking
correlation between the action potential duration and the
effective refractory period at a given endocardial site in the
human right ventricle and confirms previous in vitro findings
of a close relation between membrane repolarization and the
recurrence of excitability. Because this relation is constant
within narrow limits, provided that action potential duration
and effective refractory period measurements are made at
the same site, it may serve as a basis for detecting abnor-
malities in excitatory membrane properties caused by anti-
arrhythmic drugs or myocardial disease.
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